A vaccine against COVID-1
The three vaccines currently approved for use in the United States work by instructing the body to produce something like this. it seems as a piece of the virus, but it is not. Then, if it is ever infected with the real virus, the immune system is prepared. However, the new protein subunit vaccine already contains this important bit, known as spike protein, which means that the body does not have to produce it on its own. Moreover, the protein subunit vaccine does not require “special cooling” and also contains an “adjuvant” that makes the shot “even more protective” for NPR.
The technology itself is not new – there are hepatitis B and pertussis vaccines that use the same science. But the first iteration of COVID-19 is likely to come from biotech company Novavax, which reportedly hopes to apply for “Britain, the United States and Europe in the third quarter,” NPR said. Canadian biotechnology company Medicago and pharmaceutical giant Sanofi are also working to create their own versions. Read more on NPR.